AP

Amunix Pharmaceuticals

Closed

Mountain View, United States · $308.5M raised

Employees
11–50
Business Model
B2B
Total Funding
$308.5M
Last Round
$118.5M Series DJan 2025
Rounds
3

About

Amunix Pharmaceuticals was a Mountain View, California-based immuno-oncology company developing masked T-cell engagers and protein therapeutics for solid tumor cancers using its proprietary XTEN technology platform. The company raised $73 million in 2020 and $117 million in 2021 before being acquired by Sanofi in December 2021 for approximately $1 billion upfront, with its pipeline advancing toward clinical development. Its most advanced program, AMX-818, targeted HER2-expressing solid tumors.

Summary

Amunix Pharmaceuticals is a Biotech company based in Mountain View, United States. It has raised $308.5M in total across 3 rounds, most recently a $118.5M Series D round in Jan 2025. Investors include Viking Global and Omega Funds.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series DSeries DJan 2025
$118.5M

Sign up to see all 3 rounds

Series A through Series D — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Amunix Pharmaceuticals on Indexed.vc
<a href="https://indexed.vc/companies/amunix-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/amunix-pharmaceuticals" alt="Amunix Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>